Creative Touch Permanent Makeup and Aesthetics

Subcutaneous tissue – the hypodermis – is the deepest of the three skin layers, composed predominantly of white adipose tissue organised into adipocyte lobules separated by fibrous septa. It provides structural support, thermal insulation, energy storage, and endocrine signalling, and contributes directly to the surface architecture of skin through its volume distribution in facial and body fat compartments. With ageing, subcutaneous tissue undergoes three distinct processes that affect skin appearance: compartmental volume loss removing structural support, fat infiltration upward into the dermis impairing elasticity, and adipocyte senescence driving a local and systemic pro-inflammatory state through SASP cytokine secretion. Multiple non-invasive body contouring modalities – cryolipolysis, ultrasonic cavitation, HIEMT, radiofrequency, and deoxycholic acid injection – act on subcutaneous adipocytes through distinct mechanisms that exploit different aspects of adipocyte biology. Subcutaneous tissue is also the primary route for drug delivery of GLP-1 agonists, insulin, and biological therapies.

Subcutaneous tissue (the hypodermis) is the third and deepest layer of the skin complex, situated below the dermis and above the deep fascia or periosteum depending on anatomical location. It is not merely a passive cushioning layer – it is a metabolically active endocrine organ, a structural determinant of surface skin architecture, and a site of significant biological change with age. Its composition, distribution, and cellular behaviour are directly relevant to a wide range of aesthetic treatments and to the visible ageing changes that many of those treatments address.

Anatomy and Composition

Subcutaneous tissue is organised into lobules of adipocytes – lipid-storing cells that constitute the majority of tissue volume – separated by fibrous septa of connective tissue that anchor the layer to the overlying dermis and the underlying fascia. These septa are not uniformly distributed: in areas prone to cellulite (primarily female thighs and buttocks), the septa run perpendicularly between dermis and fascia, creating the tethered surface dimpling characteristic of that condition; in other areas they run at oblique angles, producing a smoother surface.

The vasculature, lymphatics, and sensory nerve supply of the skin all pass through subcutaneous tissue, making it anatomically relevant to any treatment that affects tissue circulation or lymphatic drainage. The lymphatic network within subcutaneous tissue is a key clearance route for the cellular debris and triglycerides produced by fat-reduction treatments – a dependency that has direct implications for post-treatment protocols and expected outcome timelines.

Adipose tissue types. Not all subcutaneous fat is metabolically identical. White adipose tissue (WAT) is the predominant form – unilocular cells storing energy as triglycerides, with endocrine function including leptin and adiponectin secretion. Brown adipose tissue (BAT) contains multilocular cells rich in mitochondria and specialised for thermogenesis through uncoupling protein-1 (UCP-1); it is most abundant in neonates but persists in adults around the supraclavicular and paraspinal regions. Beige (brite) adipocytes are white adipocytes capable of adopting a brown-like thermogenic phenotype under cold or adrenergic stimulation – a plasticity relevant to the thermogenesis debate in cryolipolysis. nature.com The functional distinction between WAT and BAT matters for treatment response: modalities that induce adrenergic stimulation (HIEMT, cold exposure) may activate beige adipocyte thermogenesis as a secondary mechanism alongside their primary fat-reduction pathway.

The stromal vascular fraction. Subcutaneous tissue is not composed solely of adipocytes. The stromal vascular fraction (SVF) – the non-adipocyte cellular component – includes preadipocytes, fibroblasts, endothelial cells, pericytes, resident macrophages, and adipose-derived stem cells (ADSCs). This cellular diversity gives subcutaneous tissue its regenerative and immune capacity; ADSCs in particular have attracted significant research interest for their ability to differentiate into multiple cell lineages and their paracrine secretion of growth factors. The SVF is also the compartment in which the inflammatory changes of ageing are initiated, through macrophage accumulation and adipocyte senescence.

Facial fat compartments. In the face, subcutaneous fat is organised into discrete anatomical compartments – superficial and deep – whose boundaries are maintained by fibrous septae and retaining ligaments. The distinct compartments of the midface (nasolabial, medial cheek, lateral cheek, infraorbital), periorbital region, forehead, and temporal fossa each age independently rather than uniformly, which is why facial volume loss produces characteristic patterns of deflation rather than global flattening. This compartmental architecture is the anatomical basis for precise aesthetic volume restoration – filling compartments in a sequence that respects their structural interdependence – and is covered in more detail in the Facial Fat Compartments entity.

Why Adipocytes Are Selectively Targetable

The ability to reduce subcutaneous fat non-invasively without damaging overlying dermis, muscle, or neurovascular structures depends on biological properties that make adipocytes specifically more vulnerable than surrounding cell types to certain physical and chemical stimuli. Understanding these selectivity mechanisms explains why non-invasive fat reduction is possible at all – and why each modality is suited to specific clinical scenarios.

Cold sensitivity differential. Adipocytes are more sensitive to cold-induced injury than dermal or epidermal cells. The high lipid content of adipocytes means their intracellular contents begin to crystallise at temperatures between approximately −1°C and +5°C – temperatures that do not initiate crystallisation in the more aqueous cytoplasm of other cell types. Cryolipolysis exploits this differential: controlled cooling to temperatures within this range triggers adipocyte crystallisation and subsequent apoptosis whilst leaving overlying dermis and epidermis physiologically intact. ^[7]

Phospholipid membrane as chemical target. The adipocyte plasma membrane, like all cell membranes, is a phospholipid bilayer – but the large volume of liquid lipid it contains makes it structurally more susceptible to membrane-disrupting agents than cells without this internal lipid load. Deoxycholic acid, a bile salt, inserts into and disrupts phospholipid bilayers, causing cellular lysis; adipocytes in the subcutaneous compartment are more densely packed with lipid and therefore more susceptible to this disruption at concentrations that produce less effect on other tissue types.

Acoustic mechanical fragility. Adipocytes have lower mechanical resistance to rapid pressure changes than the denser surrounding connective tissue. Focused ultrasound at therapeutic frequencies generates acoustic cavitation – rapidly alternating compression and rarefaction pressure waves that form and implode microbubbles – producing localised mechanical shear forces that rupture adipocyte membranes whilst leaving the fibrous septa and vasculature relatively intact. ^[1]

Electromagnetic thermal susceptibility. Radiofrequency energy heats tissue through dielectric or resistive mechanisms depending on frequency. Subcutaneous adipose tissue has different dielectric properties and lower thermal conductivity than dermis or muscle, meaning it reaches higher temperatures at equivalent RF energy input and retains heat longer. This selective thermal loading allows RF to achieve temperatures that trigger adipocyte apoptosis (approximately 43–45°C sustained) whilst the better-vascularised and more thermally conductive dermis is simultaneously stimulated for collagen remodelling rather than damaged.

Subcutaneous Tissue and Skin Ageing

The relationship between subcutaneous tissue and skin ageing involves three distinct mechanisms operating simultaneously and in different directions. Standard content addresses only the first – volume loss – leaving two important and less intuitive processes largely unexplained.

Compartmental Volume Loss

The most visible aspect of subcutaneous ageing is the loss of fat volume from facial compartments, producing the hollowing, ptosis, and loss of convex contour that characterise an aged face. As described in the Lip, Facial Fat Compartments, and Ageing Face entities, compartmental deflation removes the structural support from which overlying skin projects anteriorly, allows retaining ligaments to become relatively lax relative to reduced tissue bulk, and produces the characteristic deepening of the nasolabial folds, hollowing of the tear trough, and flattening of the midface convexity. The deflation is compartment-specific rather than global, and its sequence – typically the periorbital and medial cheek compartments earliest, the lateral cheek later – determines the progression pattern of facial ageing in most individuals. ^[18]

Fat Infiltration into the Dermis

A less intuitive but mechanistically important ageing process is the directional movement of lipid material from subcutaneous adipocytes upward into the dermis – a process sometimes called ectopic fat deposition or dermal fat infiltration. With age, the boundary between dermis and subcutaneous tissue becomes less well-defined; lipid droplets accumulate within the dermal layer, disrupting the collagen and elastin fibre architecture and impairing the mechanical properties that maintain skin elasticity and resistance to surface deformation. A 2023 PMC study confirmed that subcutaneous fat infiltration into the dermal layer produces a measurable increase in wrinkle formation and skin laxity independent of overall fat volume changes – the fat is not simply redistributing downward through gravity but actively infiltrating the layer above it. ^[4] This mechanism is structurally distinct from volumetric deflation and is not addressed by volume restoration treatments – it requires interventions that address the dermal architecture directly.

Adipocyte Senescence and Inflammageing

The most biologically significant – and most underappreciated – mechanism connecting subcutaneous tissue to skin ageing is adipocyte cellular senescence and its downstream inflammatory consequences. With age, an increasing proportion of adipocytes enter a state of permanent cell cycle arrest (senescence) without dying, and begin secreting the senescence-associated secretory phenotype (SASP) – a pro-inflammatory mixture of cytokines including IL-6, IL-8, TNF-α, and MMP-3. ^[10]

SASP secretion from senescent adipocytes operates at both local and systemic levels. Locally, the pro-inflammatory cytokine environment suppresses preadipocyte differentiation – impairing the tissue’s ability to replace lost adipocytes – whilst simultaneously degrading extracellular matrix through MMP secretion, contributing to the structural breakdown of both subcutaneous and dermal architecture. ^[15] Systemically, the sustained low-level cytokine output of senescent adipose tissue contributes to the chronic sterile inflammation of ageing – inflammageing – through the same IL-6 and TNF-α pathways implicated in cardiovascular risk, metabolic dysfunction, and the suppression of barrier protein synthesis covered in the Filaggrin, Loricrin, and Ceramides entities.

The visible marker of this process in histological sections of aged subcutaneous tissue is the crown-like structure (CLS) – a ring of infiltrating macrophages surrounding a dead or dying adipocyte. CLS density correlates with the degree of adipose tissue inflammation, insulin resistance, and systemic SASP burden, making it a histological indicator of adipose inflammageing status. ^[8]

A 2025 Nature study added a further dimension: nerve-associated macrophages – a resident macrophage population in adipose tissue that normally maintains homeostasis and restrains inflammatory activity through sympathetic nerve signalling – decline with age, removing a key regulatory brake on adipose inflammation. ^[6] The loss of this homeostatic population means age-related adipose inflammation is not simply the accumulation of pro-inflammatory signals but the simultaneous loss of the cellular mechanism that would normally restrain them.

Clinical Pearl The GLP-1 medication context is directly relevant here. Rapid subcutaneous volume loss from GLP-1 agonists (semaglutide, tirzepatide) removes facial compartment volume faster than the overlying skin can adapt through elastic recoil – a phenomenon informally termed “Ozempic face.” The mechanism is not the drug itself but the rate of subcutaneous volume loss relative to skin laxity. Clients on GLP-1 medications asking about facial aesthetics treatment need a consultation that addresses compartmental volume loss, skin laxity management, and realistic timeline expectations – not simply a reflexive offer of filler.

Treatment Mechanisms Acting on Subcutaneous Tissue

The five principal non-invasive body contouring modalities available in aesthetics each exploit a different aspect of adipocyte biology – the selectivity mechanisms described above. This section covers the mechanism, evidence basis, and clinical positioning of each. Individual treatment entities contain full protocol detail, session planning, and client experience information; this section focuses on what each modality does at the tissue level and why.

Cryolipolysis

Cryolipolysis delivers controlled, sustained cooling to subcutaneous tissue via applicator panels held against the skin surface, reducing local tissue temperature to between −1°C and +5°C for a treatment duration typically of 35–60 minutes. At this temperature range, adipocyte lipid contents begin to crystallise, initiating a sequence of cellular stress responses culminating in apoptosis – programmed cell death – rather than necrosis. The apoptosis pathway is clinically significant: necrotic cell death releases intracellular contents abruptly, producing an acute inflammatory response; apoptotic death triggers an orderly macrophage-mediated clearance process that is slower, more controlled, and produces less collateral tissue damage. ^[9]

The clearance timeline is important for managing client expectations. Following cryolipolysis, an acute inflammatory phase peaks at approximately 14 days as macrophages infiltrate and begin phagocytosing apoptotic adipocytes. This phase resolves progressively over 30–90 days, during which the cleared adipocyte volume is replaced by fibrous tissue contraction. Clinical results – measurable fat layer reduction – are typically detectable at 4 weeks and reach their maximum at 8–12 weeks. A 2024 systematic review found a mean subcutaneous fat layer reduction of 14–28% per treatment cycle, with patient satisfaction rates consistently above 70% in well-selected candidates. ^[7]

A contested secondary mechanism is cold-induced thermogenesis: the hypothesis that local cooling activates beige adipocyte UCP-1 expression, driving metabolic fat oxidation as a contribution to the overall reduction. The evidence for this pathway in cryolipolysis specifically is suggestive rather than conclusive – animal models support cold-induced beige adipocyte activation, and some human studies show elevated thermogenic markers post-treatment – but it has not been definitively separated from the apoptosis-clearance contribution. Presenting this as an established mechanism overstates the evidence; omitting it ignores a plausible contributing pathway.

Paradoxical adipose hyperplasia (PAH) is a rare but real complication in which the treated area develops a visible increase in adipose volume rather than reduction, typically appearing 2–6 months post-treatment. Its mechanism is not fully established; current evidence suggests the cold stimulus may paradoxically stimulate preadipocyte proliferation in susceptible individuals rather than triggering apoptosis. Its incidence is estimated at approximately 0.025–0.39% of treatment cycles, with higher rates in male patients and certain anatomical sites. PAH does not resolve spontaneously and typically requires surgical liposuction for correction. Honest pre-treatment disclosure of this risk is a clinical and ethical requirement.

Fat Cavitation (Ultrasonic)

Ultrasonic cavitation delivers focused low-frequency ultrasound (typically 20–80 kHz) to the subcutaneous layer, generating rapidly alternating pressure cycles within the tissue. During the rarefaction (negative pressure) phase, dissolved gases in the interstitial fluid nucleate into microbubbles; during the compression phase, these bubbles implode violently – a process called inertial cavitation. The implosion generates highly localised shear forces, temperature spikes, and hydroxyl radical production that mechanically rupture adipocyte membranes. ^[1]

The released triglycerides and cellular debris enter the interstitial fluid and are cleared predominantly via the lymphatic system to the liver, where triglycerides are processed through normal hepatic lipid metabolism. This lymphatic dependency has a direct clinical implication: clients with compromised lymphatic function – lymphoedema, post-surgical lymphatic disruption – are not suitable candidates, and post-treatment lymphatic drainage support is mechanistically rational rather than simply a commercial add-on.

Histological evidence confirms adipocyte size reduction and membrane disruption following ultrasonic cavitation treatment. Clinical volume reduction evidence is moderate rather than strong – studies demonstrate measurable circumference reduction and improved body composition markers, but results are more variable than cryolipolysis data, likely reflecting the greater sensitivity of cavitation outcomes to device parameters, operator technique, and treatment depth calibration. ^[2] Cavitation is often combined with radiofrequency in the same treatment session – cavitation reducing fat volume whilst RF addresses concurrent skin laxity – a combination with mechanistic rationale given their independent and complementary tissue targets.

HIEMT

High-intensity electromagnetic muscle training (HIEMT) delivers focused high-intensity focused electromagnetic energy to motor neurons in the target muscle group, generating supramaximal muscle contractions – contractions at an intensity that voluntary effort cannot produce because the neuromuscular system’s normal fatigue and inhibition mechanisms prevent it.

The supramaximal contraction stimulus produces two distinct tissue responses. In muscle, the extreme metabolic demand triggers adaptive hypertrophy – muscle fibre thickening and hyperplasia – through the same mTOR-mediated protein synthesis pathway as conventional resistance exercise, but at a stimulus intensity that produces more rapid adaptation. In subcutaneous tissue, the intense adrenergic stress of supramaximal contraction triggers catecholamine release that drives free fatty acid mobilisation from adjacent adipocytes via hormone-sensitive lipase – a lipolytic effect secondary to the muscle stimulus rather than a direct physical action on fat.

The clinical positioning of HIEMT is importantly distinct from the other fat-reduction modalities: it is primarily a muscle-building treatment whose secondary consequence is localised fat reduction, not primarily a fat-reduction treatment. Clients seeking fat reduction without interest in muscle development may find other modalities more appropriate; clients seeking body composition change – simultaneous fat reduction and muscle development – are the target population for HIEMT. This distinction should be explicit in consultation rather than collapsed into generic “body contouring” language.

Aqualyx (Deoxycholic Acid Injection Lipolysis)

Aqualyx is a CE-marked injectable formulation containing deoxycholic acid – a secondary bile acid produced endogenously by intestinal bacteria from primary bile acids secreted by the liver – complexed with a plant-derived galactose polymer matrix. The endogenous context is relevant: deoxycholic acid is the same molecule the digestive system uses to emulsify dietary fat for absorption. Applied to subcutaneous adipose tissue, it disrupts the phospholipid bilayer of adipocyte cell membranes, causing adipocytolysis – physical destruction of the adipocyte. ^[16]

The galactose polymer matrix in Aqualyx serves two functions: it slows the diffusion of deoxycholic acid from the injection site, reducing the risk of membrane disruption affecting non-target tissue (nerve sheaths, vascular endothelium, overlying dermis), and it allows the injection to be administered with a degree of spatial control that pure deoxycholic acid solution does not provide. Following adipocytolysis, the released lipid content and cellular debris are cleared by macrophages and the lymphatic system over a period of weeks.

The clinical significance of injection lipolysis is that adipocyte destruction is permanent – adipocytes cannot regenerate, and destroyed cells are replaced by fibrous connective tissue rather than new fat cells. This makes the fat reduction from Aqualyx durable in a way that modalities reducing adipocyte size (rather than number) are not, provided the caloric environment does not cause hypertrophy of remaining adipocytes. A 2019 systematic review of injection lipolysis found consistent evidence of measurable fat reduction in treated areas with an acceptable safety profile when administered correctly, noting that adverse effects – bruising, swelling, firmness, and rarely nodule or abscess formation – are predominantly technique-dependent. ^[16] Nodule formation, whilst uncommon, is documented and requires clinical management; clients should be counselled on this risk explicitly before treatment.

Radiofrequency (Body)

Radiofrequency body treatments heat subcutaneous tissue through dielectric energy deposition, achieving temperatures that trigger adipocyte apoptosis in the fat layer whilst simultaneously inducing controlled thermal injury in the dermis that stimulates collagen remodelling and skin tightening. This dual action – fat reduction and skin tightening in a single modality – addresses the clinical problem that fat reduction treatments alone can leave behind redundant skin, particularly in areas with pre-existing laxity or following significant volume reduction. Full mechanism detail – including heat shock protein activation, fibroblast stimulation pathways, and collagen fibre contraction – is covered in the Radiofrequency entity. ^[3]

Subcutaneous Injection

The subcutaneous route is one of the principal parenteral drug delivery routes in clinical medicine, used for insulin, GLP-1 receptor agonists (semaglutide, tirzepatide, liraglutide), low-molecular-weight heparins, and a growing range of biological therapies. Its anatomical rationale is the rich vascularity of subcutaneous tissue combined with the absence of direct muscle mass – factors that produce slower, more consistent absorption than intramuscular injection and avoid the sharp peak-and-trough pharmacokinetics associated with IM administration of drugs designed for sustained release.

Absorption from subcutaneous injection sites depends on local blood flow, injection depth, injection site (abdominal subcutaneous tissue absorbs insulin more rapidly and predictably than thigh or buttock sites), and the physicochemical properties of the formulation. GLP-1 agonists are typically injected into abdominal, thigh, or upper arm subcutaneous tissue; the once-weekly dosing of semaglutide and tirzepatide reflects formulations engineered for slow subcutaneous release rather than rapid systemic uptake.

Lipohypertrophy

Lipohypertrophy is a clinically important complication of repeated subcutaneous injection at the same site. Repeated local trauma and insulin’s lipogenic signalling causes localised adipocyte hypertrophy, producing a firm, rubbery subcutaneous mass that absorbs drug erratically – unpredictably fast or slow depending on the degree of tissue alteration. Lipohypertrophy is common in people with diabetes using insulin and is strongly associated with failure to rotate injection sites. It does not spontaneously resolve once established and can persist for months after site rotation is implemented. Clients using GLP-1 medications or insulin should be advised on injection site rotation as standard.

Facial Fat Compartments and Aesthetic Anatomy

Compartmental Architecture

The subcutaneous fat of the face is not a continuous layer that thins uniformly with age. Cadaveric dye-injection studies by ^[13] established the foundational model: the facial subcutaneous fat is organised into discrete, anatomically bounded compartments, each contained by septal barriers and supplied by an independent vascular network. Thirty hemifacial dissections confirmed that what had previously been described as a unified malar fat mass is in fact composed of three separate superficial compartments – the medial, middle, and lateral temporal-cheek fat. The forehead, orbital zone, and jowl are similarly partitioned. Septal boundaries between abutting compartments correspond to what clinicians recognise as retaining ligaments; the architecture of the compartments and the architecture of the ligamentous system are, in part, the same structure.

This compartmental model has direct clinical implications. Because each compartment has its own boundaries and vascular supply, an injection placed within one compartment does not redistribute freely into adjacent compartments. Volume placed in the superficial medial cheek fat, for example, remains confined to that territory. This independence is also why facial ageing does not produce a uniform, concentric deflation: different compartments lose volume at different rates and by different mechanisms, generating the characteristic asymmetries and irregularities of the aged face.

The Deep Facial Fat System

Beneath the superficial compartments lies a distinct deep fat system that is of greater clinical importance than its superficial counterpart in most cases of moderate-to-advanced facial ageing. The key components identified by ^[14] are:

• Deep medial cheek fat (medial and lateral compartments) – lying on the maxilla, directly deep to the malar fat. The medial component abuts the pyriform membrane; the lateral component overlies the maxilla. Loss of volume here produces pseudoptosis of the overlying superficial fat, generating the illusion of a more prominent nasolabial fold without any true descent of the malar fat pad having occurred.

• Sub-orbicularis oculi fat (SOOF) – situated deep to the orbicularis oculi muscle along the orbital rim. ^[11] confirmed two distinct SOOF regions: a medial component extending from the medial limbus to the lateral canthus, and a lateral component extending to the temporal fat pad. The medial SOOF is continuous with the deep cheek fat system across the face of the maxilla, creating a unified deep fat platform beneath the orbital rim and the midface.

• Sub-orbicularis oris fat and submentalis fat – deep fat compartments relevant to perioral volume loss and the labiomental hollow respectively, characterised by ^[12].

The conceptual architecture that emerges from these cadaveric studies is of the face as a bilaminar system: a deep fat layer that provides the structural platform and projection, and a superficial fat layer that provides surface contour and volume transitions. Ageing affects these layers unequally.

Differential Atrophy and the Mechanism of Heterogeneous Ageing

The characteristic heterogeneity of the aged face – hollowing in some zones, heaviness in others – reflects two distinct ageing processes operating on the two fat layers at different rates.

^[5] used computed tomography of twelve cadaver heads across two age groups (54–75 years and 75–104 years) to quantify midfacial fat compartment changes with age. Key findings relevant to clinical practice:

• The deep medial cheek fat shows the most pronounced compartment-specific volume loss. This is primarily an atrophic process: the tissue is lost rather than displaced.
• The superficial compartments – medial, middle, and lateral temporal-cheek fat – predominantly descend rather than atrophy. CT measurements showed that the distance between the cephalad border of these compartments and the infraorbital rim increased significantly with age, indicating inferior migration. Concurrently, volume shifted from the upper third to the lower third of each compartment, consistent with gravitational redistribution within a compartment whose ligamentous boundaries have relaxed.
• The buccal extension of the buccal fat pad behaves as an independent compartment, and its relative prominence in older subjects reflects the atrophy of the surrounding deep compartments rather than hypertrophy of the buccal fat itself.

The net clinical consequence is that the aged midface presents as the product of two concurrent changes: deep fat atrophy creating hollowing and loss of projection, combined with superficial fat descent creating heaviness in the nasolabial and jowl zones. These are mechanistically distinct, require different treatment approaches, and are often present simultaneously in the same patient.

The Malar Fat Pad: Descent Mechanism and Clinical Significance

The malar fat pad – encompassing the medial, middle, and lateral temporal-cheek superficial compartments – is the structural determinant of the midface highlight, the triangular zone of convexity that characterises youthful midface morphology. Its descent, which proceeds inferiorly and medially with age, is among the most consequential soft-tissue events in midface ageing.

The mechanism of descent is composite. ^[19] describe how reduced skeletal projection from bony resorption reduces the structural foundation upon which overlying soft tissues rest, whilst progressive laxity of the facial retaining ligaments releases the upper boundary of the compartments, allowing gravity-driven inferior displacement. Crucially, the descent of the superficial malar fat does not occur in isolation: the deep medial cheek fat atrophies simultaneously, removing the internal support platform upon which the malar compartments previously rested. The superficial fat descends into a space that has been volumetrically vacated by deep fat loss beneath it.

The clinical consequences of this composite mechanism are well recognised:

1. Nasolabial fold deepening – The descended malar fat accentuates the nasolabial fold by increasing the soft-tissue volume in the nasolabial zone. The fold itself is not created by fat; it is a fixed anatomical boundary. But the density of fat on its medial side increases as the malar compartment descends.
2. Loss of the malar highlight – Superior malar projection is lost as the malar fat descends away from the zygoma, flattening the transition from the infraorbital zone to the cheek.
3. Infraorbital hollowing – The descent of the malar fat, combined with SOOF volume loss, uncovers the inferior orbital rim, creating the skeletonised appearance associated with the tear trough and nasojugal groove.

Periorbital Compartments: The Tear Trough

The tear trough (nasojugal groove) and the infraorbital hollow are anatomically distinct regions that are often grouped clinically. From a compartmental perspective, the tear trough marks the inferior boundary of the lower eyelid preseptal fat and the transition to the SOOF. SOOF atrophy – particularly of the medial component, which underlies this transition zone – is the primary structural event behind infraorbital hollowing. As the medial SOOF thins, the inferior orbital rim becomes visible through the overlying thin skin, creating the characteristic shadowing of the tear trough. The position of the orbital rim does not change; the fat cushion anterior to it does.

This distinction matters clinically: a prominent tear trough in a younger patient typically reflects orbital fat prolapse from the fat pads anterior to the orbit (causing positive volume beneath the rim), whilst in an older patient it more commonly reflects medial SOOF atrophy and loss of the soft-tissue transition zone (causing a deficit beneath the rim). Filler placement must be calibrated to the underlying anatomy rather than to the surface appearance alone.

Perioral Compartments

The perioral zone contains both superficial and deep fat compartments that age independently of one another. ^[12] identified fat deep to the orbicularis oris and mentalis muscles – compartments distinct from the superficial lip fat. Volume loss in the sub-orbicularis oris fat is associated with loss of lip eversion and convexity of the cutaneous lip, whilst submentalis fat atrophy contributes to the labiomental hollow. The superficial cutaneous lip fat, when lost, produces vertical lip rhytides and deflation of the red lip. These are three distinct anatomical targets for distinct clinical presentations.

Commissure descent and deepening of the marionette lines reflect both inferior displacement of the jowl fat compartment (the most inferior of the superficial compartments in Rohrich & Pessa’s original map) and loss of support from the mandibular retaining ligament. Volume deficit and ligamentous laxity operate concurrently here, as they do throughout the lower face.

The Fat Compartment Framework as the Basis for Structural Filler Placement

The anatomical model described above has direct implications for filler technique. A practitioner who places hyaluronic acid filler into the superficial medial cheek fat of a patient with dominant deep medial cheek fat atrophy will restore surface volume but will not restore the structural platform that underlies it. The malar highlight will not be recreated; the facial morphology will remain consistent with ageing because the deep deficit has not been addressed. The filler has been correctly placed within a compartment, but within the wrong compartment.

The principle of structural restoration – deep before superficial, scaffold before surface – follows directly from the compartmental anatomy. ^[17] characterise this as a multilayering approach: volumisation of deep compartments to restore projection and structural support, followed by superficial compartment work to refine contour transitions. The sequence is not merely technical preference; it reflects the anatomical relationship between the layers, in which the superficial fat sits on the deep fat as a mobile drape over a structural framework.

For the midface, this translates clinically as follows:

• Deep medial cheek fat augmentation restores anterior projection, reduces pseudoptosis of the overlying malar fat, and diminishes the apparent nasolabial fold without redraping tissue superiorly.
• SOOF augmentation restores the deep fat platform beneath the orbital rim, reducing infraorbital hollowing and recreating the structural support for the lower eyelid-cheek junction.
• Superficial malar compartment augmentation, when performed after deep fat restoration, refines cheek convexity and restores the malar highlight position without adding disproportionate volume to the nasolabial region.

Vascular Architecture and Injection Safety

Each facial fat compartment has an independent perforating blood supply from named facial and deep arterial branches. Because filler placed within a compartment remains anatomically confined, the bolus volume for a given compartment is limited by the compartment’s dimensions. Overfilling a compartment risks distorting the surrounding tissue architecture, and – in the case of intravascular injection – an embolic bolus originating within a compartment will be distributed within that compartment’s vascular territory. Understanding the compartment boundaries therefore informs both the maximum safe bolus size and the zone of vascular risk for a given injection site.